Fiche publication


Date publication

mars 2023

Journal

Expert review of gastroenterology & hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent


Tous les auteurs :
Vieujean S, Louis E, Danese S, Peyrin-Biroulet L

Résumé

Ustekinumab is a humanized monoclonal antibody, targeting the p40 subunit common to both human interleukin 12 and 23, approved by the European Medicines Agency and US Food and Drug Administration for the treatment of moderate-to-severe ulcerative colitis.

Mots clés

UNIFI, efficacy, real-world studies, safety, ulcerative colitis, ustekinumab

Référence

Expert Rev Gastroenterol Hepatol. 2023 03 22;: